The dietary evidence for Crohn's disease continues to accumulate. As this paper reported yesterday, the Stanford fasting-mimicking trial published in Nature Medicine showed a 40 percent reduction in disease activity, and the University of Calgary's intermittent fasting trial found fewer flares with an eight-hour eating window. [1] ScienceDaily reported on April 3 that a new multi-site clinical trial has launched testing dietary interventions as primary treatment for inflammatory bowel disease -- not as an adjunct to medication but as a standalone therapy with clinical endpoints. [2]

The shift in framing matters more than any single data point. The medical establishment has historically treated diet as a footnote in Crohn's management -- something mentioned at the end of a clinic visit, rarely with specificity. These trials treat food as a variable to be measured, controlled, and prescribed. Stanford's data showed C-reactive protein -- a standard inflammation marker -- reduced by nearly half on the fasting-mimicking protocol. [1] That is a drug-level effect from a meal plan that costs nothing to prescribe.

The limitations remain real: small sample sizes, open-label designs, short follow-up periods. But the convergence of three independent groups finding that structured eating reduces Crohn's disease activity is harder to dismiss than any single study. For patients cycling through biologics that cost $30,000 a year, the question is no longer whether diet matters. It is why it took this long to test it properly. [3]

-- NORA WHITFIELD, Chicago